Teva got exclusivity for Risperidone tablets

Teva Pharma announced today that the U.S. District Court of Columbia has ordered that the USFDA relist in the Orange Book US5158952 and grant Teva 180-day exclusivity for a generic version of Janssen Pharmaceutical's Risperdal (Risperidone) Tablets. Teva expects final approval with exclusivity on June 29, 2008. The brand product had annual sales of approximately $2.5 billion in the United States. (Link to fdalawblog)